The following criteria is provided for health care professionals.

Inclusion Criteria:

• Must sign, and/or their legally acceptable representative where applicable must sign, a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
• Have a diagnosis of relapsed multiple myeloma [according to International Myeloma Working Group (IMWG) criteria] with 1 to 3 prior lines of therapy. (An induction regimen followed by autologous stem cell transplantation and single-agent maintenance therapy will be considered a single line of therapy.)
• Participants must have initiated a new line of induction therapy that includes a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) within 4 weeks prior to enrollment. A short course of corticosteroids is allowed prior to initiating the new line of induction therapy

Exclusion Criteria:

• Participant has plasma cell leukemia [greater than (>) 2.0 * 10^9 per liter] circulating plasma cells by standard differential), Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and/or skin changes), or amyloid light-chain amyloidosis
• Participant has a life expectancy of less than 6 months
• At the time of screening, participant is enrolled in an interventional clinical trial for multiple myeloma using an anti-neoplastic agent that is not currently approved by the United States (US) Food and Drug Administration (FDA) for this indication